Natural History of Rare Tumor Risk Syndromes: A Scoping Review to Inform Cost-Effectiveness Models
This scoping review maps the available evidence on the natural history, cancer risk, and surveillance strategies in selected Rare Tumour Risk Syndromes (RTRS) to inform disease progression models and future economic evaluations
Authors
- Stefan Aretz (ORCID: https://orcid.org/0000-0002-5228-1890)
- Joan Brunet (ORCID: https://orcid.org/0000-0003-1945-3512)
- Andrew Titman (ORCID: https://orcid.org/0000-0003-2084-0720)
- Paula Boaventura (ORCID: https://orcid.org/0000-0003-4869-8148)
- Céu Mateus (ORCID: https://orcid.org/0000-0001-6219-219X)
- Carla Oliveira (ORCID: https://orcid.org/0000-0001-8340-2264)
- Liliana Sousa
- Paula Soares
- Barbara Peleteiro
- Svetlana Bajalica Lagercrantz
- Sara Pereira
- Balmaña Judith
- Christophe Thery Jean
- Gonçalves Judite
- on behalf of PREVENTABLE Consortium
- Hoberg Vetti Hildegunn
- Schuurs Hoeijmakers Janneke
- R. Shabuz Zillur
- Di Fabrizio Carolina
Institutions
- University of Bonn (DE)
- Radboud University Nijmegen (NL)
- Inserm (FR)
- Universidade do Porto (PT)
- Catalan Institute for Water Research (ES)
- Haukeland University Hospital (NO)
- Radboud University Medical Center (NL)
- Karolinska Institutet (SE)
- Hospital de São João (PT)
- VID Specialized University (NO)
- Normandie Université (FR)
- Institut Català d'Oncologia (ES)
- Institut d'Investigació Biomèdica de Girona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto (PT)
- NOVA School of Business and Economics (PT)
- Université de Rouen Normandie (FR)
- Lancaster University (GB)
- Universidade Nova de Lisboa (PT)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-10-16
- DOI
- https://doi.org/10.5281/zenodo.23419623
- Primary Topic
- BRCA gene mutations in cancer
- Type
- preprint
Funders
- European Health and Digital Executive Agency